NASDAQ:CHRS - Coherus BioSciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.75
  • Forecasted Upside: 41.95 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$18.14
▲ +0.18 (1.00%)

This chart shows the closing price for CHRS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Coherus BioSciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CHRS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CHRS

Analyst Price Target is $25.75
▲ +41.95% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Coherus BioSciences in the last 3 months. The average price target is $25.75, with a high forecast of $30.00 and a low forecast of $22.00. The average price target represents a 41.95% upside from the last price of $18.14.

This chart shows the closing price for CHRS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Coherus BioSciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/14/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/13/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/13/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/11/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/8/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/9/2021HC WainwrightLower Price TargetBuy$36.00 ➝ $30.00High
10/6/2021HC WainwrightReiterated RatingBuy$36.00Low
8/6/2021Maxim GroupInitiated CoverageBuy$22.00Medium
7/23/2021HC WainwrightBoost Price TargetBuy$26.00 ➝ $36.00High
5/17/2021BarclaysLower Price TargetOverweight$28.00 ➝ $24.00High
5/13/2021HC WainwrightLower Price TargetBuy$29.00 ➝ $26.00Low
5/7/2021Maxim GroupInitiated CoverageBuy$22.00Low
5/7/2021HC WainwrightLower Price TargetBuy$28.00 ➝ $26.00High
2/25/2021CitigroupLower Price Target$30.00 ➝ $27.00High
2/25/2021HC WainwrightLower Price TargetBuy$33.00 ➝ $29.00High
11/19/2020MizuhoLower Price TargetBuy$35.00 ➝ $30.00Low
11/6/2020HC WainwrightLower Price TargetBuy$33.00 ➝ $32.00High
8/7/2020Maxim GroupInitiated CoverageBuy$27.00High
8/7/2020HC WainwrightBoost Price TargetBuy$30.00 ➝ $33.00Medium
7/16/2020Bank of AmericaInitiated CoverageNeutral$20.00Low
5/9/2020Maxim GroupInitiated CoverageBuy$27.00Medium
5/8/2020HC WainwrightReiterated RatingBuy$30.00High
4/17/2020SunTrust BanksInitiated CoverageBuy$26.00High
3/5/2020Credit Suisse GroupReiterated RatingBuy$36.00Low
2/29/2020Maxim GroupReiterated RatingBuy$27.00High
2/28/2020HC WainwrightBoost Price TargetBuy$29.00 ➝ $30.00High
2/6/2020JPMorgan Chase & Co.Boost Price TargetOverweight$33.00 ➝ $35.00Medium
2/4/2020MizuhoReiterated RatingBuy$43.00High
11/27/2019MizuhoInitiated CoverageBuy$43.00Medium
11/25/2019HC WainwrightReiterated RatingBuy$29.00Low
11/8/2019Credit Suisse GroupReiterated RatingBuy$36.00Low
9/29/2019MizuhoSet Price TargetBuy$43.00Medium
8/13/2019MizuhoInitiated CoverageBuy ➝ Buy$43.00Medium
8/12/2019BarclaysSet Price TargetBuy$31.00Low
8/2/2019Maxim GroupReiterated RatingBuy ➝ Buy$25.00 ➝ $27.00High
8/2/2019HC WainwrightReiterated RatingBuy ➝ Buy$28.00 ➝ $29.00High
7/10/2019Maxim GroupReiterated RatingBuy$25.00Low
6/21/2019BarclaysSet Price TargetBuy$30.00Low
6/19/2019Robert W. BairdSet Price TargetBuy$28.00Low
6/11/2019BarclaysInitiated CoverageOverweight ➝ Overweight$30.00Medium
5/10/2019Maxim GroupSet Price TargetBuy$25.00High
5/7/2019HC WainwrightInitiated CoverageBuy ➝ Buy$28.00High
4/10/2019Robert W. BairdSet Price TargetBuy$28.00Low
4/8/2019Maxim GroupReiterated RatingBuy$25.00High
3/7/2019Credit Suisse GroupSet Price TargetBuy$25.00Medium
11/5/2018HC WainwrightSet Price TargetBuy$28.00High
11/2/2018CowenReiterated RatingBuy$45.00High
9/26/2018HC WainwrightSet Price TargetBuy$28.00High
9/25/2018Maxim GroupReiterated RatingBuy$25.00Medium
8/28/2018HC WainwrightInitiated CoverageBuy ➝ Buy$28.00High
5/11/2018Maxim GroupBoost Price TargetBuy ➝ Buy$18.00 ➝ $22.00High
5/3/2018Maxim GroupSet Price TargetBuy$18.00Medium
3/9/2018CitigroupBoost Price TargetBuy ➝ Buy$23.00 ➝ $25.00Low
3/9/2018Maxim GroupReiterated RatingBuy ➝ Buy$20.00 ➝ $15.00High
11/7/2017CitigroupReiterated RatingBuy$23.00N/A
9/27/2017Credit Suisse GroupReiterated RatingOutperform$24.00 ➝ $17.00Low
9/8/2017CowenReiterated RatingOutperform$45.00Low
9/8/2017Maxim GroupReiterated RatingBuy$40.00 ➝ $20.00High
8/8/2017JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Overweight$32.00 ➝ $25.00Low
6/14/2017Credit Suisse GroupReiterated RatingOutperform$38.00 ➝ $24.00Low
6/13/2017CitigroupLower Price TargetBuy$38.00 ➝ $33.00Medium
6/13/2017CowenReiterated RatingOutperform$45.00High
6/13/2017BMO Capital MarketsLower Price TargetOutperform$54.00 ➝ $43.00High
6/13/2017Robert W. BairdLower Price TargetOutperform$40.00 ➝ $37.00High
6/12/2017Credit Suisse GroupSet Price TargetBuy$38.00Low
6/12/2017JPMorgan Chase & Co.Reiterated RatingBuyLow
6/12/2017Maxim GroupLower Price TargetBuy ➝ Buy$44.00 ➝ $40.00Medium
5/21/2017BarclaysReiterated RatingOverweight$46.00High
5/17/2017CitigroupSet Price TargetBuy$38.00High
5/15/2017BMO Capital MarketsReiterated RatingOutperform$54.00N/A
5/15/2017Maxim GroupSet Price TargetBuy$43.00Medium
5/9/2017Maxim GroupSet Price TargetBuy$43.00High
5/5/2017BMO Capital MarketsInitiated CoverageOutperform ➝ Outperform$54.00Medium
4/21/2017Credit Suisse GroupReiterated RatingBuy$38.00High
3/16/2017Credit Suisse GroupReiterated RatingBuy$38.00High
3/14/2017Maxim GroupReiterated RatingBuy$43.00Medium
2/1/2017Robert W. BairdReiterated RatingOutperform$40.00N/A
(Data available from 12/8/2016 forward)

News Sentiment Rating

0.33 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/12/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/11/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/10/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/9/2021
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/9/2021
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/8/2021
  • 2 very positive mentions
  • 6 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
12/8/2021

Current Sentiment

  • 2 very positive mentions
  • 6 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Coherus BioSciences logo
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
Read More

Today's Range

Now: $18.14
Low: $17.89
High: $18.38

50 Day Range

MA: $17.59
Low: $15.81
High: $18.99

52 Week Range

Now: $18.14
Low: $12.21
High: $22.22

Volume

558,522 shs

Average Volume

887,428 shs

Market Capitalization

$1.39 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.97

Frequently Asked Questions

What sell-side analysts currently cover shares of Coherus BioSciences?

The following equities research analysts have issued research reports on Coherus BioSciences in the last year: Barclays PLC, Citigroup Inc., HC Wainwright, Maxim Group, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for CHRS.

What is the current price target for Coherus BioSciences?

4 Wall Street analysts have set twelve-month price targets for Coherus BioSciences in the last year. Their average twelve-month price target is $25.75, suggesting a possible upside of 41.8%. HC Wainwright has the highest price target set, predicting CHRS will reach $30.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $22.00 for Coherus BioSciences in the next year.
View the latest price targets for CHRS.

What is the current consensus analyst rating for Coherus BioSciences?

Coherus BioSciences currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CHRS will outperform the market and that investors should add to their positions of Coherus BioSciences.
View the latest ratings for CHRS.

How do I contact Coherus BioSciences' investor relations team?

Coherus BioSciences' physical mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company's listed phone number is (650) 649-3530 and its investor relations email address is [email protected] The official website for Coherus BioSciences is www.coherus.com.